NEWSWATCH SEVEN AT FOUR. THE DUNHAM HOUSE BREAKS GROUND ON A PLACE FOR WOUNDED VETERANS TO GO AFTER THEIR TIME IN THE MILITARY. THANKS FOR JOINING US. I’M QUANECIA FRASER AND I’M ROB MCCARTNEY.

The suspect was shot and wounded by police officers after he disregarded their commands, the authorities said. He was taken to the hospital and identified as a student and the son of a local ...

A study shows that high-grade glioma tumor cells harboring DNA alterations in the gene PDGFRA responded to the drug avapritinib, which is already approved by the United States Food and Drug ...

The researchers obtained data on 35 individuals from the University of California San Francisco (UCSF) Adult Glioma Study,which recruited glioma cases and controls from 1991 through 2013 to ...

The glioma tumors from 17 individuals (with an average fire-fighting history of 22 years) were compared with those from 18 individuals in non-firefighting occupations.

Fractionated reirradiation is safe for recurrent high-grade glioma, with a median dose of 41.4 Gy and no critical structure injuries observed. Improved overall survival correlates with better ...

Dordaviprone has been granted Priority Review by the FDA for recurrent H3 K27M-mutant diffuse glioma, with a target action date of August 18. The drug has received Rare Pediatric Disease, Fast-Track, ...

Somatic monoallelic single nucleotide variants in the genes that encode isocitrate dehydrogenase (IDH) 1 and 2 are found in a large subset of diffusely infiltrating gliomas and subsets of acute ...

Inevitable progression Gliomas arise from glial cells, which protect and support a healthy nervous system. A substantial proportion of glioma cases are caused by mutations in IDH. "Patients ...

Glioma is a broad category of brain and spinal cord tumors that come from glial cells - brain cells that support nerve cells. The symptoms, prognosis, and treatment of a glioma depend on the ...

More information: Ilon Liu et al, GABAergic neuronal lineage development determines clinically actionable targets in diffuse hemispheric glioma, H3G34-mutant, Cancer Cell (2024). DOI: 10.1016/j ...

The US Food and Drug Administration (FDA) has approved vorasidenib (Voranigo, Servier) for the treatment of certain isocitrate dehydrogenase (IDH)–mutant diffuse gliomas, marking the first ...